Analyst Reco. Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:33:57 10/02/2026 GMT			5-day change	1st Jan Change
15.46 ^USD	+3.31%		+5.89%	-11.66%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

Analyst Reco.

12-17	Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16	MT
21/10/25	Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley…
20/10/25	Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results	CI
17/09/25	Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target	MT
04/09/25	Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target	MT
19/08/25	Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target	MT
13/08/25	Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says	MT
01/07/25	UBS Initiates Summit Therapeutics at Buy With $30 Price Target	MT
11/06/25	Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target	MT
08/05/25	TD Cowen Initiates Summit Therapeutics at Buy	MT
25/04/25	Top Midday Decliners	MT
26/03/25	Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23	MT
21/03/25	Cantor Fitzgerald Initiates Summit Therapeutics at Overweight	MT
12/03/25	Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target	MT
28/02/25	Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target	MT
08/01/25	Truist Initiates Summit Therapeutics at Buy With $35 Price Target	MT
11/12/24	Wells Fargo Initiates Summit Therapeutics at Overweight With $30 Price Target	MT
06/12/24	Jefferies Initiates Summit Therapeutics at Buy With $31 Price Target	MT
04/11/24	JMP Securities Initiates Summit Therapeutics at Market Outperform With $32 Price Target	MT
27/09/24	Citigroup Downgrades Summit Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $19	MT
03/06/24	Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	MT
07/05/24	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
26/03/24	Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target	MT
18/11/20	SUMMIT THERAPEUTICS : HC Wainwright Downgrades Summit Therapeutics to Neutral from Buy	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Analyst Reco.

Filters